PRPH dividend history

DENVER, Dec. 19, 2025 (GLOBE NEWSWIRE) -- This morning's market narrative spans futuristic materials, transformational biotech M&A, and creative capital restructuring, underscoring how innovation-driven companies are pairing long-term vision with near-term execution. Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB): Spider Silk Moves From Legend to Industrial Reality Kraig Biocraft Laboratories set a distinctive tone with a detailed Christmas shareholder letter that framed 2025 as the company's inflection year, marking its transition from prolonged development into early commercialization of recombinant spider silk. The operational message was concrete, as Kraig Labs highlighted major adv

Garden City, NY, Feb. 06, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase"), a growth oriented and diversified diagnostics, genomics and biotech company, today provided an update regarding its progress and development strategy for Linebacker-1 (LB-1), a small molecule PIM kinase inhibitor that is being developed by the Company's wholly owned subsidiary, ProPhase BioPharma, Inc. ("PBIO"), as a potential therapy enhancer for traditional chemotherapeutic agents to both increase efficacy and decrease toxicity in current cancer treatments. "We are excited to provide this update on our progress with the Linebacker-1 cancer co-therapy program, a platform which we believe ha

Company also provides additional information on ProPhase BioPharma Garden City, NY, July 26, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), a rapidly growing and diversified diagnostics, genomics and biotech company, today announced that its Board of Directors has authorized a stock repurchase program of up to $6 million in ProPhase Labs' common stock, which will become effective three business days after the date the Company issues its quarterly earnings release for the six months ended June 30, 2022 (the "Commencement Date"), which the Company currently anticipates issuing on August 12, 2022. Following the Commencement Date, and for a period of six

Anticipates Record Q4 2021 and Q1 2022 Revenues and Profits Garden City, NY, Feb. 16, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH), a diversified biotech and genomics company, announced today that its Board of Directors has declared a special cash dividend in the amount of $0.30 per share on its common stock, payable on March 10, 2022 to stockholders of record as of March 1, 2022. "Given our strong projected financial performance in net income and EBITDA for the fourth quarter of 2021, which will in turn yield significant net income and EBITDA for the full year of 2021, we believe it is appropriate to return a portion of the capital generated from operations in the form of